Table 4.
Clinical response rate (RECIST) by cancer type in patients treated with talazoparib 1.0 mg/day (recommended phase II dose)
| Response | Breasta (n = 14) | Ovarian/peritoneala (n = 12) | SCLC (n = 23) | Pancreatic (n = 10) | Ewing sarcoma (n = 13) |
|---|---|---|---|---|---|
| ORR,% | 50.0 | 41.7 | 8.7 | 20.0 | 0 |
| CR, n | 1 | 1 | 0 | 0 | 0 |
| PR, n | 6 | 4 | 2 | 2 | 0 |
| SD, n | 5 | 3 | 4 | 1 | 3 |
| CBR,%b | 85.7 | 66.7 | 26.1 | 30.0 | 23.1 |
| Median PFS, weeks | 34.6 | 36.4c | 11.1 | ND | ND |
Abbreviations: ND, not determined; SD, stable disease.
a
Patients had BRCA1/2 mutation.
b
Clinical benefit = CR + PR + SD ≥24 weeks for breast and ovarian cancers, and CR + PR + SD ≥16 weeks for SCLC, pancreatic cancer, and Ewing sarcoma.
c
Analysis on 14 patients, as 2 patients who did not have measurable disease at baseline were included in the PFS analysis but not in the response analysis.